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Metoclopramide is a peristaltic, antiemetic agent for 
short-term treatment of nausea connected with 
migraine, chemotherapy, radiotherapy and 
postoperative problems. The use of this drug is 
significantly more than domperidone and 
ondansetron. Metoclopramide is a dopamin-D2-
receptor antagonist, which at high concentrations also 
has a partial blocking and stimulating effect on 
serotonin 5-HT3 and 5-HT4-receptors. The therapeutic 
effect is achieved via receptors in the gastrointestinal 
tract, which causes increased intestinal motility, as well 
as via the chemoreceptor trigger zone in the central 
nervous system, whereby nausea is inhibited. 
Metoclopramide crosses the blood-brain barrier and 
can mediate dopamine receptor blockade in the basal 
ganglia with the risk of extrapyramidal side effects.1 
Although majority of adverse events of this drug like 
headache, diarrhea, restlessness and drowsiness are 
relatively minor, there are several that can be medically 
significant like confusion, irregularity in heartbeat, 
difficulty breathing, difficulty swallowing, seizures, 
tardive akathisia and dyskinesia, depression and 
suicidal tendencies.  This drug has the potential to 
cause drug-induced movement disorders, including 
akathisia. which is characterized by an inner 
restlessness resulting in a need for constant movement. 
We hereby report a case wherein the subject developed 
severe symptoms that were consistent with tardive 







A 32-year-old woman presented with palpitation, 
agitation and restlessness. She is a home maker, 
married and living with her husband in a metropolitan 
city, belonging to upper middle socio-economic status. 
Her medical history was significant for gall bladder 
removal after which she suffered from pain in the 
epigastric region along with other symptoms 
consistent with gastroesophageal reflux disease 
(GERD). She was given IV fluids and started with daily 
metoclopramide treatment giving good effect. She 
stayed in the hospital for a day and was discharged 
owing to relief in her symptoms. Except this she had no 
other relevant medical history, no pregnancy, no other 
comorbid conditions and also denied any incidence of 
drug allergy. After seven months of fixed treatment, 
however, she began feeling an inner sense of 
restlessness along with agitation and palpitations and 
stopped taking the medication on her husband’s 
suggestion. Her symptoms worsened and her condition 
deteriorated significantly. She experienced constant 
inner restlessness, urge to move, motor turmoil and 
chills that occurred spontaneously or were triggered by 
light touch. She regarded these movements to be 
happening spontaneously and claimed to have no 
control. She was cooperative, alert and oriented in 
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Metoclopramide is prescribed to subjects dealing with gastrointestinal issues like delayed gastric emptying, nausea, vomiting or loss 
of appetite. It is also used to treat chemotherapy and surgery related nausea and vomiting.  Although it is very effective in targeting 
stomach related illnesses, severe adverse drug reactions can occur in those who take metoclopramide.  This case report describes a 
32-year-old female who suffered from tardive akathisia while being treated with long-term metoclopramide. Long term exposure to 
causative medication leads to evolution of Tardive akathisia and this can stay for a lifetime. It is important to restrict the exposure 
duration of triggering drug. Health care professionals and patients should be well aware of this neurological adverse event of 
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questions but was a bit slow in doing this. She was 
anxious but showed a good general judgment. In her 
entire life, she had never encountered any kind of 
psychological or neurological issues. Also, she had 
never been administered metoclopramide or related 
drugs before gall bladder removal. She underwent a 
thorough investigation in the areas of neurology, 
endocrinology and internal medicine, but appeared to 
be neurological and motorically unremarkable. 
Objective and paraclinical examinations, including 
MRI scan of the cerebrum, as well as determination of 
the levels of plasma methanephrines, thyroid-
stimulating hormone and 5-hydroxyindol acetate 
showed nothing abnormal. Finally, the ongoing 
symptoms were assessed to be consistent with tardive 
akathisia secondary to long-term metoclopramide 
treatment. The subject and her husband were informed 
about the possible role of metoclopramide in her 
condition. Initially, metoclopramide treatment was 
stopped but there was no significant improvement in 
her symptoms.  Later, intravenous midazolam 
treatment was started.  Ten days later, the 
improvement in her anxiety level and involuntary 
movements was significant. Subsequently, midazolam 
was gradually stopped within a few days. One week 
after stopping midazolam, there was no recurrence of 
tardive akathisia symptoms. Her GERD medication has 
been replaced. We avoided trying metoclopramide 
again to avoid any kind of positive rechallenge. The 
subject was followed up after 1 month via a telephonic 
conversation with no complaints of tardive akathisia 
anymore.   
 
DISCUSSION 
Akathisia, which may occur as a side effect of treatment 
with dopamine receptor antagonists, is characterized 
by a feeling of inner restlessness and discomfort, as well 
as repetitive movements and a lack of ability to sit and 
stand still or unpleasant, often burning sensations in 
specific parts of the body.2 The condition is severely 
painful, but often remains undiagnosed or mistaken 
with anxiety/depression, because there is a lack of 
consensus on the diagnostic criteria.2,3 The term acute 
akathisia is used when the symptoms occur within days 
after exposure to a relevant drug and is a short-term 
condition that disappears upon the discontinuation of 
treatment. On the other hand, tardive akathisia occurs 
after prolonged exposure and may persist after 
discontinuation of the drug. Tardive akathisia belongs 
to the group of tardive syndromes, which also covers 
other movement disorders, including tardive 
dyskinesia and tardive tremor.2 The absolute risk of 
developing tardive syndromes when using 
metoclopramide is unknown, but in several studies an 
estimated risk of up to 15% has been found.1,3 Duration 
and dose are considered to be of great importance, just 
like patient-related factors such as female gender, old 
age, chronic diseases as well as the use of alcohol, 
tobacco and other neuroleptics, which increase the risk 
of the above.1-4 The primary action in the treatment is 
to discontinue the triggering substance. A slow phasing 
out is recommended, as sudden discontinuation may 
worsen or even trigger tardive syndromes.2 This could 
be due to the hypersensitivity of the dopamine 
receptors after blockade, but the pathophysiology is 
not fully clarified.1,2 Despite discontinuation of 
treatment, the symptoms may persist for years, or can 
be potentially lifelong.4 However, it is suggested that 
the condition often improves over time. The remission 
rate in previous studies varies greatly, between 2% and 
33%. Young age and early diagnosis and 
discontinuation of the triggering drug probably 
improve the prognosis.4 Tardive akathisia often does 
not respond to medical treatment, but treatment with 
tetrabenazine, which is a benzoquinolizine derivative 
with antihyperkinetic effect, is attempted in some 
persistent and disabling cases. However, the 
documentation of the efficacy of the above is sparse.2,4  
 
CONCLUSION 
Tardive akathisia is a disabling, often overlooked 
syndrome that may occur as a side effect of taking 
dopamine receptor antagonists. Metoclopramide 
should only be used for a short period of time, and 
special caution should be exercised when treating 
elderly and chronically ill patients, and the risk of 
neurological side effects should be kept in mind. 
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